Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation
Recruiting now · Phase 1
Conditions studied: Hematologic Diseases
In brief
This study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but lack suitable donors. This project plans to use human leukocyte antigen (HLA) mismatched donors. Ultimately, a HLA mismatched allo HSCT transplantation plan will be established to improve the disease prognosis of these patients and truly enter the era of "everyone has a donor".
Key facts
- Study ID
- NCT06809699
- Run by
- He Huang
- People needed
- 29
- Starts
- 2022-08-04
- Expected to finish
- 2027-10-31
- Last updated by the study team
- 2025-02-05
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult patients (18-60 years old) with hematological malignancies and indications for hematopoietic stem cell transplantation with no available related human leukocyte antigen (HLA) identical sibling donors;
- No available donor with HLA high-resolution typing ≥ 9/10 or those who have difficulty finding donors due to urgent medical conditions;
- No suitable HLA matching haploidentical donor available;
- There is a suitable donor with mismatched HLA typing;
- The subjects or their legal representatives shall sign an informed consent form before the start of the clinical study.
You may not qualify if…
- Patients with severe liver and kidney function (alanine aminotransferase>2.5 times the upper limit of normal, blood creatinine>1.5 times the upper limit of normal) and cardiopulmonary dysfunction (New York Heart Association (NYHA) III/IV heart function, ejection fraction<50%, severe obstructive or restrictive ventilation dysfunction);
- Merge active infections;
- Eastern Cooperative Oncology Group (ECOG) score ≥ 2 points;
- Secondary tumors with merged activity;
- Severe central nervous system or mental illness leading to the inability to autonomously choose to enter or exit clinical trials;
- Combine other allo HSCT contraindications.
Where it is running
- The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, China, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.